{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:29:22Z","timestamp":1794047362688,"version":"4.8.0"},"reference-count":143,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"9","license":[{"start":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T00:00:00Z","timestamp":1593734400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Chronic lymphocytic leukemia is a well-defined lymphoid neoplasm with very heterogeneous biological and clinical behavior. The last decade has been remarkably fruitful in novel findings elucidating multiple aspects of the pathogenesis of the disease including mechanisms of genetic susceptibility, insights into the relevance of immunogenetic factors driving the disease, profiling of genomic alterations, epigenetic subtypes, global epigenomic tumor cell reprogramming, modulation of tumor cell and microenvironment interactions, and dynamics of clonal evolution from early steps in monoclonal B cell lymphocytosis to progression and transformation into diffuse large B-cell lymphoma. All this knowledge has offered new perspectives that are being exploited therapeutically with novel target agents and management strategies. In this review we provide an overview of these novel advances and highlight questions and perspectives that need further progress to translate into the clinics the biological knowledge and improve the outcome of the patients.<\/jats:p>","DOI":"10.3324\/haematol.2019.236000","type":"journal-article","created":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T16:25:13Z","timestamp":1593707113000},"page":"2205-2217","source":"Crossref","is-referenced-by-count":91,"title":["Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies"],"prefix":"10.3324","volume":"105","author":[{"family":"Julio Delgado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Ferran Nadeu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Dolors Colomer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Elias Campo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2020,7,3]]},"reference":[{"key":"2277","unstructured":"Campo E, Ghia P, Montserrat E, M\u00fcller-Hermelink HK, Stein H, Swerdlow SH. Chronic lymphocytic leukaemia\/small lymphocytic lymphoma. 2017;216-221. Google Scholar"},{"key":"2278","unstructured":"Howlader N, Noone A, Krapcho M. SEER Cancer Statistics Review, 1975-2016, National Cancer Institute.Google Scholar"},{"key":"2279","unstructured":"Puente XS, Be\u00e0 S, Vald\u00e9s-Mas R. Noncoding recurrent mutations in chronic lymphocytic leukaemia. Nature. 2015; 526(7574):519-524. Google Scholar"},{"key":"2280","doi-asserted-by":"crossref","unstructured":"Landau DA, Tausch E, Taylor-Weiner AN. Mutations driving CLL and their evolution in progression and relapse. Nature. 2015; 526(7574):525-530. Google Scholar","DOI":"10.1038\/nature15395"},{"key":"2281","doi-asserted-by":"crossref","unstructured":"Kulis M, Heath S, Bibikova M. Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nat Genet. 2012; 44(11):1236-1242. Google Scholar","DOI":"10.1038\/ng.2443"},{"key":"2282","doi-asserted-by":"crossref","unstructured":"Beekman R, Chapaprieta V, Russi\u00f1ol N. The reference epigenome and regulatory chromatin landscape of chronic lymphocytic leukemia. Nat Med. 2018; 24(6):868-880. Google Scholar","DOI":"10.1038\/s41591-018-0028-4"},{"key":"2283","doi-asserted-by":"crossref","unstructured":"Oakes CC, Claus R, Gu L. Evolution of DNA methylation is linked to genetic aberrations in chronic lymphocytic leukemia. Cancer Discov. 2014; 4(3):348-361. Google Scholar","DOI":"10.1158\/2159-8290.CD-13-0349"},{"key":"2284","unstructured":"Berndt SI, Camp NJ, Skibola CF. Metaanalysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia. Nat Commun. 2016; 7(1):10933. Google Scholar"},{"key":"2285","doi-asserted-by":"crossref","unstructured":"Speedy HE, Beekman R, Chapaprieta V. Insight into genetic predisposition to chronic lymphocytic leukemia from integrative epigenomics. Nat Commun. 2019; 10(1):3615. Google Scholar","DOI":"10.1038\/s41467-019-11582-2"},{"key":"2286","doi-asserted-by":"crossref","unstructured":"Kikushige Y, Ishikawa F, Miyamoto T. Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia. Cancer Cell. 2011; 20(2):246-259. Google Scholar","DOI":"10.1016\/j.ccr.2011.06.029"},{"key":"2287","doi-asserted-by":"crossref","unstructured":"Landau DA, Carter SL, Stojanov P. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell. 2013; 152(4):714-726. Google Scholar","DOI":"10.1016\/j.cell.2013.01.019"},{"key":"2288","doi-asserted-by":"crossref","unstructured":"Nadeu F, Delgado J, Royo C. Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia. Blood. 2016; 127(17):2122-2130. Google Scholar","DOI":"10.1182\/blood-2015-07-659144"},{"key":"2289","doi-asserted-by":"crossref","unstructured":"Nadeu F, Clot G, Delgado J. Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia. Leukemia. 2018; 32(3):645-653. Google Scholar","DOI":"10.1038\/leu.2017.291"},{"key":"2290","doi-asserted-by":"crossref","unstructured":"Agathangelidis A, Ljungstr\u00f6m V, Scarf\u00f2 L. Highly similar genomic landscapes in monoclonal b-cell lymphocytosis and ultrastable chronic lymphocytic leukemia with low frequency of driver mutations. Haematologica. 2018; 103(5):865-873. Google Scholar","DOI":"10.3324\/haematol.2017.177212"},{"key":"2291","doi-asserted-by":"crossref","unstructured":"Brazdilova K, Plevova K, Skuhrova Francova H. Multiple productive IGH rearrangements denote oligoclonality even in immunophenotypically monoclonal CLL. Leukemia. 2018; 32(1):234-236. Google Scholar","DOI":"10.1038\/leu.2017.274"},{"key":"2292","doi-asserted-by":"crossref","unstructured":"Plevova K, Francova HS, Burckova K. Multiple productive immunoglobulin heavy chain gene rearrangements in chronic lymphocytic leukemia are mostly derived from independent clones. Haematologica. 2014; 99(2):329-338. Google Scholar","DOI":"10.3324\/haematol.2013.087593"},{"key":"2293","doi-asserted-by":"crossref","unstructured":"Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999; 94(6):1848-1854. Google Scholar","DOI":"10.1182\/blood.V94.6.1848.418k05_1848_1854"},{"key":"2294","doi-asserted-by":"crossref","unstructured":"Damle RN, Wasil T, Fais F. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999; 94(6):1840-1847. Google Scholar","DOI":"10.1182\/blood.V94.6.1840.418k06_1840_1847"},{"key":"2295","doi-asserted-by":"crossref","unstructured":"Seifert M, Sellmann L, Bloehdorn J. Cellular origin and pathophysiology of chronic lymphocytic leukemia. J Exp Med. 2012; 209(12):2183-2198. Google Scholar","DOI":"10.1084\/jem.20120833"},{"key":"2296","doi-asserted-by":"crossref","unstructured":"Stamatopoulos K, Agathangelidis A, Rosenquist R, Ghia P.. Antigen receptor stereotypy in chronic lymphocytic leukemia. Leukemia. 2017; 31(2):282-291. Google Scholar","DOI":"10.1038\/leu.2016.322"},{"key":"2297","doi-asserted-by":"crossref","unstructured":"Jaramillo S, Agathangelidis A, Schneider C. Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG). Haematologica. 2019. Google Scholar","DOI":"10.3324\/haematol.2019.231027"},{"key":"2298","doi-asserted-by":"crossref","unstructured":"D\u00fchren-von Minden M, \u00dcbelhart R, Schneider D. Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature. 2012; 489(7415):309-312. Google Scholar","DOI":"10.1038\/nature11309"},{"key":"2299","doi-asserted-by":"crossref","unstructured":"Minici C, Gounari M, \u00dcbelhart R. Distinct homotypic B-cell receptor interactions shape the outcome of chronic lymphocytic leukaemia. Nat Commun. 2017; 8(1):15746. Google Scholar","DOI":"10.1038\/ncomms15746"},{"key":"2300","doi-asserted-by":"crossref","unstructured":"Maity PC, Bilal M, Koning MT. IGLV3-21\u221701 is an inherited risk factor for CLL through the acquisition of a single-point mutation enabling autonomous BCR signaling. Proc Natl Acad Sci U S A. 2020; 117(8):4320-4327. Google Scholar","DOI":"10.1073\/pnas.1913810117"},{"key":"2301","doi-asserted-by":"crossref","unstructured":"Stamatopoulos B, Smith T, Crompot E. The light chain IgLV3-21 defines a new poor prognostic subgroup in chronic lymphocytic leukemia: results of a multicenter study. Clin Cancer Res. 2018; 24(20):5048-5057. Google Scholar","DOI":"10.1158\/1078-0432.CCR-18-0133"},{"key":"2302","doi-asserted-by":"crossref","unstructured":"Oakes CC, Seifert M, Assenov Y. DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia. Nat Genet. 2016; 48(3):253-264. Google Scholar","DOI":"10.1038\/ng.3488"},{"key":"2303","doi-asserted-by":"crossref","unstructured":"Queir\u00f3s AC, Villamor N, Clot G. A Bcell epigenetic signature defines three biologic subgroups of chronic lymphocytic leukemia with clinical impact. Leukemia. 2015; 29(3):598-605. Google Scholar","DOI":"10.1038\/leu.2014.252"},{"key":"2304","doi-asserted-by":"crossref","unstructured":"Wojdacz TK, Amarasinghe HE, Kadalayil L. Clinical significance of DNA methylation in chronic lymphocytic leukemia patients: results from 3 UK clinical trials. Blood Adv. 2019; 3(16):2474-2481. Google Scholar","DOI":"10.1182\/bloodadvances.2019000237"},{"key":"2305","doi-asserted-by":"crossref","unstructured":"Herndon TM, Chen SS, Saba NS. Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood. Leukemia. 2017; 31(6):1340-1347. Google Scholar","DOI":"10.1038\/leu.2017.11"},{"key":"2306","doi-asserted-by":"crossref","unstructured":"ten Hacken E, Burger JA. Microenvironment interactions and B-cell receptor signaling in chronic lymphocytic leukemia: Implications for disease pathogenesis and treatment. Biochim Biophys Acta. 2016; 1863(3):401-413. Google Scholar","DOI":"10.1016\/j.bbamcr.2015.07.009"},{"key":"2307","doi-asserted-by":"crossref","unstructured":"Herreros B, Rodr\u00edguez-Pinilla SM, Pajares R. Proliferation centers in chronic lymphocytic leukemia: the niche where NF-B activation takes place. Leukemia. 2010; 24(4):872-876. Google Scholar","DOI":"10.1038\/leu.2009.285"},{"key":"2308","doi-asserted-by":"crossref","unstructured":"Herishanu Y, P\u00e9rez-Gal\u00e1n P, Liu D. The lymph node microenvironment promotes Bcell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood. 2011; 117(2):563-574. Google Scholar","DOI":"10.1182\/blood-2010-05-284984"},{"key":"2309","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-Guerra M, Xargay-Torrent S, Rosich L. The -secretase inhibitor PF- 03084014 combined with fludarabine antagonizes migration, invasion and angiogenesis in NOTCH1-mutated CLL cells. Leukemia. 2015; 29(1):96-106. Google Scholar","DOI":"10.1038\/leu.2014.143"},{"key":"2310","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-Guerra M, Xargay-Torrent S, Fuentes P. Specific NOTCH1 antibody targets DLL4-induced proliferation, migration, and angiogenesis in NOTCH1-mutated CLL cells. Oncogene. 2020; 39(6):1185-1197. Google Scholar","DOI":"10.1038\/s41388-019-1053-6"},{"key":"2311","doi-asserted-by":"crossref","unstructured":"Arruga F, Bracciam\u00e0 V, Vitale N. Bidirectional linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and in Richter\u2019s syndrome: therapeutic implications. Leukemia. 2020; 34(2):462-477. Google Scholar","DOI":"10.1038\/s41375-019-0571-0"},{"key":"2312","unstructured":"Puente XS, Pinyol M, Quesada V. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature. 2011; 475(7354):101-105. Google Scholar"},{"key":"2313","doi-asserted-by":"crossref","unstructured":"Hanna BS, \u00d6zt\u00fcrk S, Seiffert M.. Beyond bystanders: myeloid cells in chronic lymphocytic leukemia. Mol Immunol. 2019; 110(1):77-87. Google Scholar","DOI":"10.1016\/j.molimm.2017.11.014"},{"key":"2314","doi-asserted-by":"crossref","unstructured":"Riches JC, Davies JK, McClanahan F. T cells from CLL patients exhibit features of Tcell exhaustion but retain capacity for cytokine production. Blood. 2013; 121(9):1612-1621. Google Scholar","DOI":"10.1182\/blood-2012-09-457531"},{"key":"2315","doi-asserted-by":"crossref","unstructured":"Ramsay AG, Evans R, Kiaii S, Svensson L, Hogg N, Gribben JG. Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide. Blood. 2013; 121(14):2704-2714. Google Scholar","DOI":"10.1182\/blood-2012-08-448332"},{"key":"2316","doi-asserted-by":"crossref","unstructured":"Hanna BS, Roessner PM, Yazdanparast H. Control of chronic lymphocytic leukemia development by clonally-expanded CD8+ T-cells that undergo functional exhaustion in secondary lymphoid tissues. Leukemia. 2019; 33(3):625-637. Google Scholar","DOI":"10.1038\/s41375-018-0250-6"},{"key":"2317","doi-asserted-by":"crossref","unstructured":"Lla\u00f3 Cid L, Hanna BS, Iskar M. CD8+ T-cells of CLL-bearing mice acquire a transcriptional program of T-cell activation and exhaustion. Leuk Lymphoma. 2020; 61(2):351-356. Google Scholar","DOI":"10.1080\/10428194.2019.1660972"},{"key":"2318","doi-asserted-by":"crossref","unstructured":"Kipps TJ, Stevenson FK, Wu CJ. Chronic lymphocytic leukaemia. Nat Rev Dis Prim. 2017;316096. Google Scholar","DOI":"10.1038\/nrdp.2016.96"},{"key":"2319","doi-asserted-by":"crossref","unstructured":"Wiestner A. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia. Haematologica. 2015; 100(12):1495-1507. Google Scholar","DOI":"10.3324\/haematol.2014.119123"},{"key":"2320","doi-asserted-by":"crossref","unstructured":"Mockridge CI, Potter KN, Wheatley I, Neville LA, Packham G, Stevenson FK. Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status. Blood. 2007; 109(10):4424-4431. Google Scholar","DOI":"10.1182\/blood-2006-11-056648"},{"key":"2321","doi-asserted-by":"crossref","unstructured":"Moore VDG, Brown JR, Certo M, Love TM, Novina CD, Letai A.. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest. 2007; 117(1):112-121. Google Scholar","DOI":"10.1172\/JCI28281"},{"key":"2322","doi-asserted-by":"crossref","unstructured":"Juliusson G, Oscier DG, Fitchett M. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N Engl J Med. 1990; 323(11):720-724. Google Scholar","DOI":"10.1056\/NEJM199009133231105"},{"key":"2323","doi-asserted-by":"crossref","unstructured":"D\u00f6hner H, Stilgenbauer S, Benner A. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000; 343(26):1910-1916. Google Scholar","DOI":"10.1056\/NEJM200012283432602"},{"key":"2324","doi-asserted-by":"crossref","unstructured":"Haferlach C, Dicker F, Schnittger S, Kern W, Haferlach T.. Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping. Leukemia. 2007; 21(12):2442-2451. Google Scholar","DOI":"10.1038\/sj.leu.2404935"},{"key":"2325","doi-asserted-by":"crossref","unstructured":"Baliakas P, Iskas M, Gardiner A. Chromosomal translocations and karyotype complexity in chronic lymphocytic leukemia: a systematic reappraisal of classic cytogenetic data. Am J Hematol. 2014; 89(3):249-255. Google Scholar","DOI":"10.1002\/ajh.23618"},{"key":"2326","doi-asserted-by":"crossref","unstructured":"Huh YO, Abruzzo L V., Rassidakis GZ. The t(14;19)(q32;q13)-positive small B-cell leukaemia: a clinicopathologic and cytogenetic study of seven cases. Br J Haematol. 2007; 136(2):220-228. Google Scholar","DOI":"10.1111\/j.1365-2141.2006.06416.x"},{"key":"2327","doi-asserted-by":"crossref","unstructured":"Nadeu F, Diaz-Navarro A, Delgado J, Puente XS, Campo E.. Genomic and epigenomic alterations in chronic lymphocytic leukemia. Annu Rev Pathol Mech Dis. 2020; 15(1):149-177. Google Scholar","DOI":"10.1146\/annurev-pathmechdis-012419-032810"},{"key":"2328","doi-asserted-by":"crossref","unstructured":"Edelmann J, Holzmann K, Miller F. High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations. Blood. 2012; 120(24):4783-4794. Google Scholar","DOI":"10.1182\/blood-2012-04-423517"},{"key":"2329","doi-asserted-by":"crossref","unstructured":"Delgado J, Salaverria I, Baumann T. Genomic complexity and IGHV mutational status are key predictors of outcome of chronic lymphocytic leukemia patients with TP53 disruption. Haematologica. 2014; 99(11):e231-e234. Google Scholar","DOI":"10.3324\/haematol.2014.108365"},{"key":"2330","doi-asserted-by":"crossref","unstructured":"Thompson PA, Stingo F, Keating MJ. Outcomes of patients with chronic lymphocytic leukemia treated with first-line idelalisib plus rituximab after cessation of treatment for toxicity. Cancer. 2016; 122(16):2505-2511. Google Scholar","DOI":"10.1002\/cncr.30069"},{"key":"2331","doi-asserted-by":"crossref","unstructured":"Baliakas P, Jeromin S, Iskas M. Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact. Blood. 2019; 133(11):1205-1216. Google Scholar","DOI":"10.1182\/blood-2018-09-873083"},{"key":"2332","doi-asserted-by":"crossref","unstructured":"Baliakas P, Puiggros A, Xochelli A. Additional trisomies amongst patients with chronic lymphocytic leukemia carrying trisomy 12: the accompanying chromosome makes a difference. Haematologica. 2016; 101(7):299-302. Google Scholar","DOI":"10.3324\/haematol.2015.140202"},{"key":"2333","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-Trillos A, Pinyol M, Navarro A. Mutations in TLR\/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome. Blood. 2014; 123(24):3790-3796. Google Scholar","DOI":"10.1182\/blood-2013-12-543306"},{"key":"2334","doi-asserted-by":"crossref","unstructured":"Gim\u00e9nez N, Mart\u00ednez-Trillos A, Montraveta A. Mutations in the RAS-BRAF-MAPKERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia. Haematologica. 2019; 104(3):576-586. Google Scholar","DOI":"10.3324\/haematol.2018.196931"},{"key":"2335","doi-asserted-by":"crossref","unstructured":"Stilgenbauer S, Schnaiter A, Paschka P. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood. 2014; 123(21):3247-3254. Google Scholar","DOI":"10.1182\/blood-2014-01-546150"},{"key":"2336","doi-asserted-by":"crossref","unstructured":"Malcikova J, Tausch E, Rossi D. ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia - update on methodological approaches and results interpretation. Leukemia. 2018; 32(5):1070-1080. Google Scholar","DOI":"10.1038\/s41375-017-0007-7"},{"key":"2337","doi-asserted-by":"crossref","unstructured":"Sutton L-A, Ljungstr\u00f6m V, Enjuanes A. Comparative analysis of targeted next-generation sequencing panels for the detection of gene mutations in chronic lymphocytic leukemia: an ERIC multi-center study. Haematologica. 2020. Google Scholar","DOI":"10.3324\/haematol.2019.234716"},{"key":"2338","doi-asserted-by":"crossref","unstructured":"Rossi D, Khiabanian H, Spina V. Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. Blood. 2014; 123(14):2139-2147. Google Scholar","DOI":"10.1182\/blood-2013-11-539726"},{"key":"2339","doi-asserted-by":"crossref","unstructured":"Ojha J, Ayres J, Secreto C. Deep sequencing identifies genetic heterogeneity and recurrent convergent evolution in chronic lymphocytic leukemia. Blood. 2015; 125(3):492-498. Google Scholar","DOI":"10.1182\/blood-2014-06-580563"},{"key":"2340","doi-asserted-by":"crossref","unstructured":"Amin NA, Seymour E, Saiya-Cork K, Parkin B, Shedden K, Malek SN. A quantitative analysis of subclonal and clonal gene mutations before and after therapy in chronic lymphocytic leukemia. Clin Cancer Res. 2016; 22(17):4525-4535. Google Scholar","DOI":"10.1158\/1078-0432.CCR-15-3103"},{"key":"2341","doi-asserted-by":"crossref","unstructured":"Landau DA, Sun C, Rosebrock D. The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy. Nat Commun. 2017; 8(1):2185. Google Scholar","DOI":"10.1038\/s41467-017-02329-y"},{"key":"2342","doi-asserted-by":"crossref","unstructured":"Blombery P, Anderson MA, Gong JN. Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia. Cancer Discov. 2019; 9(3):342-353. Google Scholar","DOI":"10.1158\/2159-8290.CD-18-1119"},{"key":"2343","doi-asserted-by":"crossref","unstructured":"Lampson BL, Brown JR. Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?. Expert Rev Hematol. 2018; 11(3):185-194. Google Scholar","DOI":"10.1080\/17474086.2018.1435268"},{"key":"2344","doi-asserted-by":"crossref","unstructured":"Zhao X, Lwin T, Silva A. Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma. Nat Commun. 2017; 8(1):14920. Google Scholar","DOI":"10.1038\/ncomms14920"},{"key":"2345","doi-asserted-by":"crossref","unstructured":"Agarwal R, Chan YC, Tam CS. Dynamic molecular monitoring reveals that SWI\u2013SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma. Nat Med. 2019; 25(1):119-129. Google Scholar","DOI":"10.1038\/s41591-018-0243-z"},{"key":"2346","doi-asserted-by":"crossref","unstructured":"Pan R, Ruvolo V, Mu H. Synthetic lethality of combined Bcl-2 inhibition and p53 activation in AML: mechanisms and superior antileukemic efficacy. Cancer Cell. 2017; 32(6):748-760. Google Scholar","DOI":"10.1016\/j.ccell.2017.11.003"},{"key":"2347","doi-asserted-by":"crossref","unstructured":"Landau DA, Clement K, Ziller MJ. Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia. Cancer Cell. 2014; 26(6):813-825. Google Scholar","DOI":"10.1016\/j.ccell.2014.10.012"},{"key":"2348","doi-asserted-by":"crossref","unstructured":"Ott CJ, Federation AJ, Schwartz LS. Enhancer architecture and essential core regulatory circuitry of chronic lymphocytic leukemia. Cancer Cell. 2018; 34(6):982-995.e7. Google Scholar","DOI":"10.1016\/j.ccell.2018.11.001"},{"key":"2349","doi-asserted-by":"crossref","unstructured":"Mallm J, Iskar M, Ishaque N. Linking aberrant chromatin features in chronic lymphocytic leukemia to transcription factor networks. Mol Syst Biol. 2019; 15(5):e8339. Google Scholar","DOI":"10.15252\/msb.20188339"},{"key":"2350","doi-asserted-by":"crossref","unstructured":"Pastore A, Gaiti F, Lu SX. Corrupted coordination of epigenetic modifications leads to diverging chromatin states and transcriptional heterogeneity in CLL. Nat Commun. 2019; 10(1):1874. Google Scholar","DOI":"10.1038\/s41467-019-09645-5"},{"key":"2351","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez D, Bretones G, Quesada V. Mutations in CHD2 cause defective association with active chromatin in chronic lymphocytic leukemia. Blood. 2015; 126(2):195-202. Google Scholar","DOI":"10.1182\/blood-2014-10-604959"},{"key":"2352","doi-asserted-by":"crossref","unstructured":"Tsagiopoulou M, Chapaprieta V, Duran-Ferrer M. Chronic lymphocytic leukemias with trisomy 12 show a distinct DNA methylation profile linked to altered chromatin activation. Haematologica. 2020. Google Scholar","DOI":"10.3324\/haematol.2019.240721"},{"key":"2353","doi-asserted-by":"crossref","unstructured":"Landgren O, Albitar M, Ma W. B-cell clones as early markers for chronic lymphocytic leukemia. N Engl J Med. 2009; 360(7):659-667. Google Scholar","DOI":"10.1056\/NEJMoa0806122"},{"key":"2354","doi-asserted-by":"crossref","unstructured":"Criado I, Rodr\u00edguez-Caballero A, Guti\u00e9rrez ML. Low-count monoclonal B-cell lymphocytosis persists after seven years of follow up and is associated with a poorer outcome. Haematologica. 2018; 103(7):1198-1208. Google Scholar","DOI":"10.3324\/haematol.2017.183954"},{"key":"2355","doi-asserted-by":"crossref","unstructured":"Rawstron AC, Bennett FL, O\u2019Connor SJM. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med. 2008; 359(6):575-583. Google Scholar","DOI":"10.1056\/NEJMoa075290"},{"key":"2356","doi-asserted-by":"crossref","unstructured":"Rossi D, Spina V, Gaidano G.. Biology and treatment of Richter syndrome. Blood. 2018; 131(25):2761-2772. Google Scholar","DOI":"10.1182\/blood-2018-01-791376"},{"key":"2357","doi-asserted-by":"crossref","unstructured":"Del Giudice I, Chiaretti S, Tavolaro S. Spontaneous regression of chronic lymphocytic leukemia: clinical and biologic features of 9 cases. Blood. 2009; 114(3):638-646. Google Scholar","DOI":"10.1182\/blood-2008-12-196568"},{"key":"2358","doi-asserted-by":"crossref","unstructured":"Barrio S, Shanafelt TD, Ojha J. Genomic characterization of high-count MBL cases indicates that early detection of driver mutations and subclonal expansion are predictors of adverse clinical outcome. Leukemia. 2017; 31(1):170-176. Google Scholar","DOI":"10.1038\/leu.2016.172"},{"key":"2359","doi-asserted-by":"crossref","unstructured":"Winkelmann N, Rose-Zerilli M, Forster J. Low frequency mutations independently predict poor treatment-free survival in early stage chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Haematologica. 2015; 100(6):e237-e239. Google Scholar","DOI":"10.3324\/haematol.2014.120238"},{"key":"2360","doi-asserted-by":"crossref","unstructured":"Gruber M, Bozic I, Leshchiner I. Growth dynamics in naturally progressing chronic lymphocytic leukaemia. Nature. 2019; 570(7762):474-479. Google Scholar","DOI":"10.1038\/s41586-019-1252-x"},{"key":"2361","doi-asserted-by":"crossref","unstructured":"Montserrat E, Sanchez\u2010Bisono J, Vi\u00f1olas N, Rozman C.. Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance. Br J Haematol. 1986; 62(3):567-575. Google Scholar","DOI":"10.1111\/j.1365-2141.1986.tb02969.x"},{"key":"2362","doi-asserted-by":"crossref","unstructured":"Hallek M, Cheson BD, Catovsky D. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018; 131(25):2745-2760. Google Scholar","DOI":"10.1182\/blood-2017-09-806398"},{"key":"2363","doi-asserted-by":"crossref","unstructured":"Al-Sawaf O, Robrecht S, Bahlo J. Richter transformation in chronic lymphocytic leukemia (CLL)\u2014a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials. Leukemia. 2020. Google Scholar","DOI":"10.1038\/s41375-020-0797-x"},{"key":"2364","doi-asserted-by":"crossref","unstructured":"Fabbri G, Khiabanian H, Holmes AB. Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome. J Exp Med. 2013; 210(11):2273-2288. Google Scholar","DOI":"10.1084\/jem.20131448"},{"key":"2365","doi-asserted-by":"crossref","unstructured":"Kadri S, Lee J, Fitzpatrick C. Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL. Blood Adv. 2017; 1(12):715-727. Google Scholar","DOI":"10.1182\/bloodadvances.2016003632"},{"key":"2366","doi-asserted-by":"crossref","unstructured":"Miller CR, Ruppert AS, Heerema NA. Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib. Blood Adv. 2017; 1(19):1584-1588. Google Scholar","DOI":"10.1182\/bloodadvances.2017007302"},{"key":"2367","doi-asserted-by":"crossref","unstructured":"Kwok M, Oldreive C, Rawstron AC. Integrative analysis of spontaneous CLL regression highlights genetic and microenvironmental interdependency in CLL. Blood. 2020; 135(6):411-428. Google Scholar","DOI":"10.1182\/blood.2019001262"},{"key":"2368","doi-asserted-by":"crossref","unstructured":"Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975; 46(2):219-234. Google Scholar","DOI":"10.1182\/blood.V46.2.219.bloodjournal462219"},{"key":"2369","doi-asserted-by":"crossref","unstructured":"Binet JL, Auquier A, Dighiero G. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981; 48(1):198-206. Google Scholar","DOI":"10.1002\/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V"},{"key":"2370","doi-asserted-by":"crossref","unstructured":"Baliakas P, Hadzidimitriou A, Sutton L-A. Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia. 2015; 29(2):329-336. Google Scholar","DOI":"10.1038\/leu.2014.196"},{"key":"2371","doi-asserted-by":"crossref","unstructured":"Rossi D, Rasi S, Spina V. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood. 2013; 121(8):1403-1412. Google Scholar","DOI":"10.1182\/blood-2012-09-458265"},{"key":"2372","doi-asserted-by":"crossref","unstructured":"Baliakas P, Moysiadis T, Hadzidimitriou A. Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia. Haematologica. 2019; 104(2):360-369. Google Scholar","DOI":"10.3324\/haematol.2018.195032"},{"key":"2373","doi-asserted-by":"crossref","unstructured":"International CLL-IPI working groups. An international prognostic index for patients with chronic lymphocytic leukaemia (CLLIPI): a meta-analysis of individual patient data. Lancet Oncol. 2016; 17(6):779-790. Google Scholar","DOI":"10.1016\/S1470-2045(16)30029-8"},{"key":"2374","doi-asserted-by":"crossref","unstructured":"da Cunha-Bang C, Christiansen I, Niemann CU. The CLL-IPI applied in a populationbased cohort. Blood. 2016; 128(17):2181-2183. Google Scholar","DOI":"10.1182\/blood-2016-07-724740"},{"key":"2375","doi-asserted-by":"crossref","unstructured":"Molica S, Shanafelt TD, Giannarelli D. The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients. Am J Hematol. 2016; 91(11):1090-1095. Google Scholar","DOI":"10.1002\/ajh.24493"},{"key":"2376","doi-asserted-by":"crossref","unstructured":"Gentile M, Shanafelt TD, Rossi D. Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients. Blood. 2016; 128(16):2093-2095. Google Scholar","DOI":"10.1182\/blood-2016-07-728261"},{"key":"2377","doi-asserted-by":"crossref","unstructured":"Delgado J, Doubek M, Baumann T. Chronic lymphocytic leukemia: a prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI. Am J Hematol. 2017; 92(4):375-380. Google Scholar","DOI":"10.1002\/ajh.24660"},{"key":"2378","doi-asserted-by":"crossref","unstructured":"Condoluci A, Terzi di Bergamo L, Langerbeins P. International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. Blood. 2020; 135(21):1859-1869. Google Scholar","DOI":"10.1182\/blood.2019003453"},{"key":"2379","doi-asserted-by":"crossref","unstructured":"Dighiero G, Maloum K, Desablens B. Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. N Engl J Med. 1998; 338(21):1506-1514. Google Scholar","DOI":"10.1056\/NEJM199805213382104"},{"key":"2380","doi-asserted-by":"crossref","unstructured":"Herling CD, Cymbalista F, Gro\u00df-Ophoff-M\u00fcller C. Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial. Leukemia. 2020. Google Scholar","DOI":"10.1038\/s41375-020-0747-7"},{"key":"2381","doi-asserted-by":"crossref","unstructured":"Langerbeins P, Bahlo J, Rhein C. Ibrutinib versus placebo in patients with asymptomatic treatment-na\u00efve early stage CLL: primary endpoint results of the phase 3 double-blind randomized CLL12 trial. Hematol Oncol. 2019; 37(Suppl 2):38-40. Google Scholar","DOI":"10.1002\/hon.7_2629"},{"key":"2382","doi-asserted-by":"crossref","unstructured":"Burger JA, Tedeschi A, Barr PM. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015; 373(25):2425-2437. Google Scholar","DOI":"10.1056\/NEJMoa1509388"},{"key":"2383","doi-asserted-by":"crossref","unstructured":"Shanafelt TD, Wang X V., Kay NE. Ibrutinib\u2013rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019; 381(5):432-443. Google Scholar","DOI":"10.1056\/NEJMoa1817073"},{"key":"2384","doi-asserted-by":"crossref","unstructured":"Woyach JA, Ruppert AS, Heerema NA. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018; 379(26):2517-2528. Google Scholar","DOI":"10.1056\/NEJMoa1812836"},{"key":"2385","doi-asserted-by":"crossref","unstructured":"Moreno C, Greil R, Demirkan F. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019; 20(1):43-56. Google Scholar","DOI":"10.1016\/S1470-2045(18)30788-5"},{"key":"2386","doi-asserted-by":"crossref","unstructured":"Burger JA, Sivina M, Jain N. Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood. 2019; 133(10):1011-1019. Google Scholar","DOI":"10.1182\/blood-2018-10-879429"},{"key":"2387","unstructured":"Diop F, Moia R, Favini C. Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia. Haematologica. 2020; 105(2):448-456. Google Scholar"},{"key":"2388","doi-asserted-by":"crossref","unstructured":"Tausch E, Schneider C, Robrecht S. Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax. Blood. 2020. Google Scholar","DOI":"10.1182\/blood.2019004492"},{"key":"2389","doi-asserted-by":"crossref","unstructured":"Fischer K, Al-Sawaf O, Bahlo J. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019; 380(23):2225-2236. Google Scholar","DOI":"10.1056\/NEJMoa1815281"},{"key":"2390","doi-asserted-by":"crossref","unstructured":"Sharman JP, Egyed M, Jurczak W. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020; 395(10232):1278-1291. Google Scholar","DOI":"10.1016\/S0140-6736(20)30262-2"},{"key":"2391","doi-asserted-by":"crossref","unstructured":"Byrd JC, Furman RR, Coutre SE. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013; 369(1):32-42. Google Scholar","DOI":"10.1056\/NEJMoa1215637"},{"key":"2392","doi-asserted-by":"crossref","unstructured":"Farooqui MZH, Valdez J, Martyr S. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncol. 2015; 16(2):169-176. Google Scholar","DOI":"10.1016\/S1470-2045(14)71182-9"},{"key":"2393","doi-asserted-by":"crossref","unstructured":"O\u2019Brien S, Jones JA, Coutre SE. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol. 2016; 17(10):1409-1418. Google Scholar","DOI":"10.1016\/S1470-2045(16)30212-1"},{"key":"2394","unstructured":"Byrd JC, Brown JR, O\u2019Brien S. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014; 371(3):213-223. Google Scholar"},{"key":"2395","doi-asserted-by":"crossref","unstructured":"Chanan-Khan A, Cramer P, Demirkan F. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol. 2016; 17(2):200-211. Google Scholar","DOI":"10.1016\/S1470-2045(15)00465-9"},{"key":"2396","doi-asserted-by":"crossref","unstructured":"Roberts AW, Davids MS, Pagel JM. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016; 374(4):311-322. Google Scholar","DOI":"10.1056\/NEJMoa1513257"},{"key":"2397","doi-asserted-by":"crossref","unstructured":"Stilgenbauer S, Eichhorst B, Schetelig J. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016; 17(6):768-778. Google Scholar","DOI":"10.1016\/S1470-2045(16)30019-5"},{"key":"2398","doi-asserted-by":"crossref","unstructured":"Jones JA, Mato AR, Wierda WG. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018; 19(1):65-75. Google Scholar","DOI":"10.1016\/S1470-2045(17)30909-9"},{"key":"2399","doi-asserted-by":"crossref","unstructured":"Coutre S, Choi M, Furman RR. Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy. Blood. 2018; 131(15):1704-1711. Google Scholar","DOI":"10.1182\/blood-2017-06-788133"},{"key":"2400","doi-asserted-by":"crossref","unstructured":"Seymour JF, Kipps TJ, Eichhorst B. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018; 378(12):1107-1120. Google Scholar","DOI":"10.1056\/NEJMoa1713976"},{"key":"2401","doi-asserted-by":"crossref","unstructured":"Furman RR, Sharman JP, Coutre SE. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014; 370(11):997-1007. Google Scholar","DOI":"10.1056\/NEJMoa1315226"},{"key":"2402","doi-asserted-by":"crossref","unstructured":"Sharman JP, Coutre SE, Furman RR. Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia. J Clin Oncol. 2019; 37(16):1391-1402. Google Scholar","DOI":"10.1200\/JCO.18.01460"},{"key":"2403","doi-asserted-by":"crossref","unstructured":"Kreuzer KA, Furman RR, Stilgenbauer S. The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab. Leukemia. 2020; 34(1):296-300. Google Scholar","DOI":"10.1038\/s41375-019-0533-6"},{"key":"2404","doi-asserted-by":"crossref","unstructured":"Anderson MA, Tam C, Lew TE. Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax. Blood. 2017; 129(25):3362-3370. Google Scholar","DOI":"10.1182\/blood-2017-01-763003"},{"key":"2405","doi-asserted-by":"crossref","unstructured":"Maddocks KJ, Ruppert AS, Lozanski G. Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA. Oncol. 2015; 1(1):80-87. Google Scholar","DOI":"10.1001\/jamaoncol.2014.218"},{"key":"2406","doi-asserted-by":"crossref","unstructured":"Flinn IW, Hillmen P, Montillo M. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL\/SLL. Blood. 2018; 132(23):2446-2455. Google Scholar","DOI":"10.1182\/blood-2018-05-850461"},{"key":"2407","doi-asserted-by":"crossref","unstructured":"Ghia P, Pluta A, Wach M. ASCEND: phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2020. Google Scholar","DOI":"10.1200\/JCO.19.03355"},{"key":"2408","doi-asserted-by":"crossref","unstructured":"Awan FT, Schuh A, Brown JR. Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. Blood Adv. 2019; 3(9):1553-1562. Google Scholar","DOI":"10.1182\/bloodadvances.2018030007"},{"key":"2409","doi-asserted-by":"crossref","unstructured":"Gribben JG. How and when I do allogeneic transplant in CLL. Blood. 2018; 132(1):31-39. Google Scholar","DOI":"10.1182\/blood-2018-01-785998"},{"key":"2410","doi-asserted-by":"crossref","unstructured":"Kharfan-Dabaja MA, Kumar A, Hamadani M. Clinical practice recommendations for use of allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia on behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2016; 22(12):2117-2125. Google Scholar","DOI":"10.1016\/j.bbmt.2016.09.013"},{"key":"2411","doi-asserted-by":"crossref","unstructured":"Dreger P, Ghia P, Schetelig J. High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies. Blood. 2018; 132(9):892-902. Google Scholar","DOI":"10.1182\/blood-2018-01-826008"},{"key":"2412","doi-asserted-by":"crossref","unstructured":"Bair SM, Porter DL. Accelerating chimeric antigen receptor therapy in chronic lymphocytic leukemia: the development and challenges of chimeric antigen receptor T-cell therapy for chronic lymphocytic leukemia. Am J Hematol. 2019; 94(S1):S10-S17. Google Scholar","DOI":"10.1002\/ajh.25457"},{"key":"2413","doi-asserted-by":"crossref","unstructured":"Sutton LA, Young E, Baliakas P. Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors. Haematologica. 2016; 101(8):959-967. Google Scholar","DOI":"10.3324\/haematol.2016.141812"},{"key":"2414","doi-asserted-by":"crossref","unstructured":"Burger JA, Chiorazzi N.. B cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol. 2013; 34(12):592-601. Google Scholar","DOI":"10.1016\/j.it.2013.07.002"},{"key":"2415","doi-asserted-by":"crossref","unstructured":"Burger JA, Quiroga MP, Hartmann E. High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood. 2009; 113(13):3050-3058. Google Scholar","DOI":"10.1182\/blood-2008-07-170415"},{"key":"2416","doi-asserted-by":"crossref","unstructured":"Dilillo DJ, Weinberg JB, Yoshizaki A. Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function. Leukemia. 2013; 27(1):170-182. Google Scholar","DOI":"10.1038\/leu.2012.165"},{"key":"2417","doi-asserted-by":"crossref","unstructured":"Lewinsky H, Barak AF, Huber V. CD84 regulates PD-1\/PD-L1 expression and function in chronic lymphocytic leukemia. J Clin Invest. 2018; 128(12):5479-5488. Google Scholar","DOI":"10.1172\/JCI96610"},{"key":"2418","doi-asserted-by":"crossref","unstructured":"De Matteis S, Molinari C, Abbati G. Immunosuppressive Treg cells acquire the phenotype of effector-T cells in chronic lymphocytic leukemia patients. J Transl Med. 2018; 16(1):172. Google Scholar","DOI":"10.1186\/s12967-018-1545-0"},{"key":"2419","doi-asserted-by":"crossref","unstructured":"Paggetti J, Haderk F, Seiffert M. Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts. Blood. 2015; 126(9):1106-1117. Google Scholar","DOI":"10.1182\/blood-2014-12-618025"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/9796\/71009","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/9796\/71010","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/9796\/71009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T09:57:32Z","timestamp":1794045452000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/9796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,3]]},"references-count":143,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,8,21]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2019.236000","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7,3]]}}}